Clinical Trial Update: Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating selinexor combined with an anti-PD-1 antibody and the Pegaspargase-Gemcitabine-Oxaliplatin regimen for relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• Anti-PD-1 antibody
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Pegaspargase (pegaspargase)
• Selinexor (selinexor)

Snippet

Sponsor: Ruijin Hospital | Conditions: Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING